Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$4.45
0.020.45%
At close: -
$4.43
-0.02-0.45%
After Hours: 6:28 PM EDT
Comments
Loading...
Myriad Genetics Analyst Ratings and Price Targets | NASDAQ:MYGN | Benzinga
Myriad Genetics Inc has a consensus price target of $17.12 based on the ratings of 19 analysts. The high is $30 issued by TD Cowen on August 7, 2024. The low is $6 issued by Wells Fargo on May 8, 2025. The 3 most-recent analyst ratings were released by Piper Sandler, Wells Fargo, and Goldman Sachs on May 15, 2025, May 8, 2025, and May 7, 2025, respectively. With an average price target of $7.67 between Piper Sandler, Wells Fargo, and Goldman Sachs, there's an implied 73.06% upside for Myriad Genetics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Wells Fargo
Goldman Sachs
UBS
Raymond James
1calculated from analyst ratings
Analyst Ratings for Myriad Genetics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/15/2025 | Buy Now | 103.16% | Piper Sandler | Dave Weiner44% | $12.5 → $9 | Maintains | Overweight | Get Alert |
| 05/08/2025 | Buy Now | 35.44% | Wells Fargo | Brandon Couillard69% | $22 → $6 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 05/07/2025 | Buy Now | 80.59% | Goldman Sachs | Matthew Sykes62% | $14 → $8 | Maintains | Buy | Get Alert |
| 05/07/2025 | Buy Now | 58.01% | UBS | Lu Li14% | $16 → $7 | Maintains | Neutral | Get Alert |
| 05/07/2025 | Buy Now | 125.73% | Raymond James | Andrew Cooper53% | $19 → $10 | Reiterates | Outperform → Outperform | Get Alert |
| 04/17/2025 | Buy Now | 216.03% | Goldman Sachs | Matthew Sykes62% | $18 → $14 | Maintains | Buy | Get Alert |
| 04/09/2025 | Buy Now | — | Guggenheim | Subbu Nambi42% | — | Downgrade | Buy → Neutral | Get Alert |
| 04/01/2025 | Buy Now | 351.47% | Scotiabank | Sung Ji Nam44% | $24 → $20 | Maintains | Sector Outperform | Get Alert |
| 03/12/2025 | Buy Now | 182.17% | Piper Sandler | Dave Weiner44% | $11.5 → $12.5 | Upgrade | Neutral → Overweight | Get Alert |
| 03/04/2025 | Buy Now | 159.59% | Piper Sandler | Dave Weiner44% | $14 → $11.5 | Maintains | Neutral | Get Alert |
| 03/03/2025 | Buy Now | 148.31% | B of A Securities | Derik De Bruin84% | $13 → $11 | Maintains | Underperform | Get Alert |
| 02/25/2025 | Buy Now | 328.89% | Raymond James | Andrew Cooper53% | $27 → $19 | Reiterates | Outperform → Outperform | Get Alert |
| 02/25/2025 | Buy Now | 261.17% | UBS | Lu Li14% | $18 → $16 | Maintains | Neutral | Get Alert |
| 02/12/2025 | Buy Now | 554.63% | Craig-Hallum | John Wilkin24% | → $29 | Initiates | → Buy | Get Alert |
| 01/30/2025 | Buy Now | 216.03% | Piper Sandler | John Peterson1% | $24 → $14 | Maintains | Neutral | Get Alert |
| 01/28/2025 | Buy Now | 306.32% | Goldman Sachs | Matthew Sykes62% | $29 → $18 | Maintains | Buy | Get Alert |
| 01/16/2025 | Buy Now | 351.47% | Stephens & Co. | Mason Carrico39% | $20 → $20 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 12/13/2024 | Buy Now | 193.45% | B of A Securities | Derik De Bruin84% | $15 → $13 | Maintains | Underperform | Get Alert |
| 12/10/2024 | Buy Now | 306.32% | UBS | Lu Li14% | → $18 | Initiates | → Neutral | Get Alert |
| 12/09/2024 | Buy Now | 374.04% | Leerink Partners | Puneet Souda56% | $30 → $21 | Downgrade | Outperform → Market Perform | Get Alert |
| 11/18/2024 | Buy Now | 374.04% | Morgan Stanley | Tejas Savant50% | $32 → $21 | Maintains | Equal-Weight | Get Alert |
| 11/11/2024 | Buy Now | 441.76% | Piper Sandler | John Peterson1% | $30 → $24 | Maintains | Neutral | Get Alert |
| 09/19/2024 | Buy Now | 622.35% | Morgan Stanley | Tejas Savant50% | → $32 | Initiates | → Equal-Weight | Get Alert |
| 08/27/2024 | Buy Now | 690.07% | Wells Fargo | Brandon Couillard69% | → $35 | Initiates | → Overweight | Get Alert |
| 08/13/2024 | Buy Now | 667.49% | Scotiabank | Sung Ji Nam44% | $29 → $34 | Maintains | Sector Outperform | Get Alert |
| 08/13/2024 | Buy Now | 577.2% | Piper Sandler | John Peterson1% | $28 → $30 | Maintains | Neutral | Get Alert |
| 08/07/2024 | Buy Now | 577.2% | TD Cowen | Dan Brennan61% | $28 → $30 | Maintains | Hold | Get Alert |
| 08/07/2024 | Buy Now | 351.47% | JP Morgan | Rachel Vatnsdal65% | $17 → $20 | Maintains | Underweight | Get Alert |
| 06/27/2024 | Buy Now | 554.63% | Scotiabank | Sung Ji Nam44% | → $29 | Initiates | → Sector Outperform | Get Alert |
| 06/03/2024 | Buy Now | 351.47% | Jefferies | Tycho Peterson83% | $25 → $20 | Assumes | Hold → Underperform | Get Alert |
| 05/13/2024 | Buy Now | 532.05% | Piper Sandler | John Peterson1% | $23 → $28 | Maintains | Neutral | Get Alert |
| 05/08/2024 | Buy Now | 690.07% | Leerink Partners | Puneet Souda56% | $25 → $35 | Upgrade | Market Perform → Outperform | Get Alert |
| 01/30/2024 | Buy Now | 599.77% | Goldman Sachs | Matthew Sykes62% | $28 → $31 | Maintains | Buy | Get Alert |
| 01/29/2024 | Buy Now | 599.77% | Goldman Sachs | Matthew Sykes62% | $28 → $31 | Maintains | Buy | Get Alert |
| 12/21/2023 | Buy Now | 419.19% | Piper Sandler | John Peterson1% | → $23 | Initiates | → Neutral | Get Alert |
| 12/19/2023 | Buy Now | 351.47% | Wells Fargo | Timothy Daley53% | → $20 | Initiates | → Equal-Weight | Get Alert |
| 12/14/2023 | Buy Now | 419.19% | Guggenheim | Subbu Nambi42% | → $23 | Initiates | → Buy | Get Alert |
| 12/13/2023 | Buy Now | — | Wolfe Research | Doug Schenkel72% | — | Initiates | → Outperform | Get Alert |
| 11/07/2023 | Buy Now | 216.03% | JP Morgan | Rachel Vatnsdal65% | $17 → $14 | Maintains | Underweight | Get Alert |
| 08/07/2023 | Buy Now | 283.75% | JP Morgan | Rachel Vatnsdal65% | $18 → $17 | Maintains | Underweight | Get Alert |
| 07/24/2023 | Buy Now | 532.05% | Goldman Sachs | Matthew Sykes62% | $25 → $28 | Maintains | Buy | Get Alert |
| 07/21/2023 | Buy Now | 532.05% | Goldman Sachs | Matthew Sykes62% | $25 → $28 | Maintains | Buy | Get Alert |
| 05/24/2023 | Buy Now | 464.33% | Goldman Sachs | Matthew Sykes62% | $18 → $25 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | 464.33% | Goldman Sachs | Matthew Sykes62% | $18 → $25 | Upgrade | Sell → Buy | Get Alert |
| 05/04/2023 | Buy Now | 306.32% | Goldman Sachs | Matthew Sykes62% | $20 → $18 | Maintains | Sell | Get Alert |
| 05/04/2023 | Buy Now | 441.76% | Stephens & Co. | Mason Carrico39% | → $24 | Reiterates | → Equal-Weight | Get Alert |
| 03/06/2023 | Buy Now | 441.76% | Stephens & Co. | Mason Carrico39% | $17 → $24 | Maintains | Equal-Weight | Get Alert |
| 03/03/2023 | Buy Now | 509.48% | Raymond James | Andrew Cooper53% | $25 → $27 | Maintains | Outperform | Get Alert |
| 01/18/2023 | Buy Now | 464.33% | Raymond James | Andrew Cooper53% | → $25 | Upgrade | Market Perform → Outperform | Get Alert |
| 11/02/2022 | Buy Now | 464.33% | SVB Leerink | Puneet Souda56% | $27 → $25 | Maintains | Market Perform | Get Alert |
| 10/06/2022 | Buy Now | 396.61% | Stephens & Co. | Mason Carrico39% | → $22 | Initiates | → Equal-Weight | Get Alert |
| 08/05/2022 | Buy Now | 577.2% | SVB Leerink | Puneet Souda56% | $26 → $30 | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Myriad Genetics (MYGN) stock?
The latest price target for Myriad Genetics (NASDAQ:MYGN) was reported by Piper Sandler on May 15, 2025. The analyst firm set a price target for $9.00 expecting MYGN to rise to within 12 months (a possible 103.16% upside). 30 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Myriad Genetics (MYGN)?
The latest analyst rating for Myriad Genetics (NASDAQ:MYGN) was provided by Piper Sandler, and Myriad Genetics maintained their overweight rating.
When was the last upgrade for Myriad Genetics (MYGN)?
The last upgrade for Myriad Genetics Inc happened on March 12, 2025 when Piper Sandler raised their price target to $12.5. Piper Sandler previously had a neutral for Myriad Genetics Inc.
When was the last downgrade for Myriad Genetics (MYGN)?
The last downgrade for Myriad Genetics Inc happened on May 8, 2025 when Wells Fargo changed their price target from $22 to $6 for Myriad Genetics Inc.
When is the next analyst rating going to be posted or updated for Myriad Genetics (MYGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Myriad Genetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Myriad Genetics was filed on May 15, 2025 so you should expect the next rating to be made available sometime around May 15, 2026.
Is the Analyst Rating Myriad Genetics (MYGN) correct?
While ratings are subjective and will change, the latest Myriad Genetics (MYGN) rating was a maintained with a price target of $12.50 to $9.00. The current price Myriad Genetics (MYGN) is trading at is $4.43, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
